Crispr Therapeutics
Zug, Switzerland · Biotechnology, Genetics, Healthcare
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas
Key facts
- Headquarters
- Zug, Switzerland
- Employees
- 344
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (CRSP)
- Website
- crisprtx.com
- Company page
Recent activity at Crispr Therapeutics
- : Crispr Therapeutics names Sivakesava Sakhamuri Chief Technical Officer
- : CRISPR Therapeutics Appoints Andrew J. Silver as Chief Financial Officer
- : SEC 8-K (5.02): CRISPR Therapeutics AG announced the appointment of Andrew J. Silver as Chief Financial Officer, effective immediately on October 19, 2026. Previously serving as Senior Vice President of Finance since January 2025, Mr. Silver has an extensive background in finance and accounting, having spent over 10 years at Ernst & Young LLP. His new role comes with an annual salary of $515,000, a target annual bonus of 45%, and a one-time grant of 25,000 restricted stock units that will vest in two years, contingent upon continued service. The Employment Agreement includes provisions for termination with a six-month notice period if he is let go without cause or resigns for good reason.
- : SEC 8-K (5.02): On June 4, 2026, the shareholders of CRISPR Therapeutics AG approved the 2026 Stock Option and Incentive Plan during the 2026 Annual General Meeting. This plan reserves shares for issuance that were previously allocated under the 2018 Stock Option and Incentive Plan, along with any shares from awards that may be forfeited or terminated. The plan includes various types of stock awards and will adjust the number of shares eligible for issuance if the company's capital structure changes due to events like stock splits or dividends. The plan's details are further outlined in the definitive proxy statement filed on April 21, 2026.
- : SEC 8-K (1.01): On March 16, 2026, CRISPR Therapeutics AG entered into a material definitive agreement by completing a private offering of $600.0 million in Convertible Senior Notes due March 1, 2031. This offering included an additional $50.0 million due to the full exercise of the initial purchasers' option. The effective coupon was set at 1.7308% after adjusting for anticipated withholding under Swiss tax law, aimed at mitigating tax impacts on investors. With net proceeds of approximately $585.2 million, the Company plans to utilize the funds for general corporate purposes. The notes feature a conversion rate of 13.0617 common shares per $1,000 principal amount, which equates to an initial price of about $76.56 per share, representing a significant premium to the latest stock price of $52.80 on March 10, 2026.
- : SEC 8-K (8.01): On March 10, 2026, CRISPR Therapeutics AG announced the commencement of a private offering of $350.0 million aggregate principal amount of convertible senior notes due 2031. This offering is aimed at qualified institutional buyers under Rule 144A of the Securities Act. On March 11, 2026, the company revealed an upsized offering, increasing the total amount to $550 million. The press releases related to these announcements indicate that the offering is subject to market conditions and thus highlights significant financial maneuvering designed to bolster capital structure.
- : SEC 8-K (8.01): On January 12, 2026, CRISPR Therapeutics AG issued a press release detailing recent advancements in its gene editing programs, particularly in cardiovascular and autoimmune diseases. The company highlighted progress in its CTX310 clinical trials targeting severe hypertriglyceridemia, which has shown promising results in reducing triglycerides and LDL levels. Additionally, it reported advancements for CTX320 and CTX321, as well as ongoing collaborations with Eli Lilly for zugo-cel in treating aggressive B-cell lymphomas, which signifies significant strategic partnerships and potential market expansions. Importantly, all mentioned developments reinforce the company's commitment to innovative therapies in critical health areas, with ongoing clinical trials and new candidate programs in the pipeline.
- : SEC 8-K (8.01): CRISPR Therapeutics AG (the 'Company') filed a prospectus supplement on October 15, 2025, to offer and sell additional Common Shares at an aggregate price of up to $600,000,000 through Jefferies LLC, as per their Open Market Sale Agreement originally entered into on August 30, 2019. This offering will utilize the Company's automatically effective shelf registration statement filed on August 5, 2024. The filing does not constitute an offer to sell the securities in jurisdictions where such offers may be unlawful without proper registration or qualification. This significant offer aims to increase the Company's capital raising capabilities through equity capital markets, reflecting its ongoing business strategy and market conditions.
- : SEC 8-K (8.01): On October 15, 2025, CRISPR Therapeutics AG entered into an amended Open Market Sale Agreement with Jefferies LLC, allowing the Company to offer and sell additional Common Shares with an aggregate offering price of up to $600,000,000. This additional offering will be executed at the Company's sole discretion through Jefferies as its sales agent. The shares will be sold under the previously filed shelf registration statement on Form S-3ASR, indicating a strategic move to potentially raise significant capital for future initiatives or operational expansions. The transaction builds on an earlier agreement made on August 30, 2019.
- : CRISPR Therapeutics Appoints Naimish Patel as Chief Medical Officer and Julianne Bruno as Chief Operating Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Crispr Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2020 | Seed | $1.0M |
| Nov 2016 | Venture | $35.0M |
Leadership
- Rodger Novak, Executive Officer, Director
- Samarth Kulkarni, Executive Officer, Director
- Ali Behbahani, Director
- Bradley Bolzon, Director
- Simeon George, Director
- Katherine High, Director
- John Greene, Director
Verified email and direct lines for Crispr Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Crispr Therapeutics in the news
- CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference - Yahoo Finance UK (May 06, 2026)
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - GlobeNewswire (Aug 03, 2026)
- Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes - Business Wire (Mar 24, 2023)
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewswire (May 04, 2026)
- CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - GlobeNewswire (Jan 12, 2026)
- CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies - GlobeNewswire (May 19, 2025)
Companies similar to Crispr Therapeutics
- Passage Bio · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Elevation Oncology · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Solid Biosciences · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Wave Life Sciences · Biotechnology, Healthcare, Health Care, Therapeutics
- Renibus Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About Crispr Therapeutics: questions and answers
What does Crispr Therapeutics do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas
Where is Crispr Therapeutics headquartered?
Crispr Therapeutics is headquartered in Zug, Switzerland.
How many employees does Crispr Therapeutics have?
Crispr Therapeutics has about 344 employees.
Has Crispr Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Crispr Therapeutics. The most recent, Seed of $1.0M, was in Apr 2020.
What is the latest news on Crispr Therapeutics?
On Nov 3, 2026, Crispr Therapeutics names Sivakesava Sakhamuri Chief Technical Officer
Is Crispr Therapeutics a public company?
Yes. Crispr Therapeutics is publicly traded under the ticker CRSP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy